Acute Spinal Cord Injury Clinical Trial
— SCINGOfficial title:
Spinal Cord Injury Neuroprotection With Glyburide; Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury
Verified date | June 2022 |
Source | Ohio State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the safety of using oral Glyburide in patients with acute traumatic cervical spinal cord injuries (SCI).
Status | Terminated |
Enrollment | 3 |
Est. completion date | February 8, 2021 |
Est. primary completion date | February 8, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age: = 18 years and = 80 years 2. Written informed consent by patient or legal authorized representative 3. No other life-threatening injury 4. No evidence of sepsis 5. Acute cervical SCI with ASIA Impairment Scale grade A, B or C on admission 6. Non-penetrating SCI at neurologic level from C2 to C8 7. Initiation of study drug within 8 hours of injury Exclusion Criteria 1. Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours 2. Acute SCI with ASIA Impairment Scale grade D or E 3. Currently involved in another non-observational SCI research study or receiving another investigational drug 4. History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components 5. Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation (at discretion of the site investigator) 6. Unable to commit to the follow-up schedule 7. A recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study 8. Any condition likely to result in the patient's death within the next 12 months 9. Prisoner 10. Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of < 30 mL/min/1.73 m2 11. Known severe liver disease, or ALT > 3 times upper limit of normal or bilirubin > 2 times upper limit normal. Subjects may be randomized if liver function tests have been drawn but are not yet available and the subject has no known history of liver disease; however, treatment with DiaBeta will be discontinued prior to the second dose if liver function tests indicate ALT > 3 times upper limit of normal or bilirubin > 2 times upper limit of normal 12. Blood glucose <55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia 13. Acute ST elevation myocardial infarction, and/or acute decompensated heart failure, and/or QTc > 520 ms, and/or known history of cardiac arrest (PEA, VT, VF, asystole), and/or admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months 14. Known treatment with Bosentan within past 7 days 15. Known G6PD enzyme deficiency 16. Pregnancy: Women must be either post-menopausal, permanently sterilized or, if = 50 years old, must have a negative test for pregnancy obtained before enrollment 17. Breast-feeding women who do not agree to stop breast-feeding during and for 7 days following the end of oral glyburide administration 18. Subjects who in the opinion of the investigator are not suitable for inclusion in the study (reason to be documented). |
Country | Name | City | State |
---|---|---|---|
United States | The Ohio State University | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With tSCI Recruited Within the Specified Time Window | A measure of feasibility of undertaking a larger phase II study among this population of patients where treatment must begin within a short injury-to-drug time window. | Enrollment Period (within 8 hours of tSCI) | |
Primary | Number of Drug Related Adverse Events | A measure of safety of treating patients with traumatic spinal cord injury with Glyburide administered orally within a short injury-to-drug time window. | One year post enrollment | |
Secondary | Number of Participants With Neurologic Recovery Following tSCI | The neurologic status of patients will be assessed using the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as assessed by International Standards for Neurological Classification of SCI (ISNCSCI) criteria. | One year post enrollment | |
Secondary | Serum Pharmacokinetic and Biomarker Analysis | Plasma concentrations will be serially quantified through day 3 following tSCI to evaluate the pharmacokinetics of Glyburide in the acute tSCI population. Comparisons will be made to reported levels achieved in healthy patient cohorts. Standard enzyme-linked immunosorbent assay (ELISA) techniques will be used to measure blood levels of neurofilament light chain, neuron- specific enolase, tau, S100b, and glial fibrillary acidic protein levels on admission, at 24 hours and on days 3 and 7 following tSCI to evaluate serum biomarker levels. Comparisons will be made to previously published values observed in non-treated control patients | Enrollment through post-treatment day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04811235 -
Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial
|
N/A | |
Completed |
NCT00406016 -
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
|
Phase 1 | |
Recruiting |
NCT05305118 -
TSCS for Acute SCI
|
N/A | |
Recruiting |
NCT05244408 -
"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation
|
||
Recruiting |
NCT05731986 -
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
|
N/A | |
Recruiting |
NCT06452264 -
Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study
|
N/A | |
Recruiting |
NCT05426681 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1 | |
Recruiting |
NCT04056988 -
tSCI Contrast Enhanced Ultrasound Study
|
Phase 4 | |
Recruiting |
NCT05745298 -
The Use of Functional Electrical Stimulation in Conjunction With Respiratory Muscle Training to Improve Unaided Cough in Individuals With Acute Spinal Cord Injury
|
N/A | |
Terminated |
NCT01750684 -
AC105 in Patients With Acute Traumatic Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT04475224 -
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
|
Phase 3 | |
Enrolling by invitation |
NCT06030531 -
Spasticity and Functional Recovery After SCI
|
||
Active, not recruiting |
NCT03935724 -
Stem Cells in Spinal Cord Injury
|
Phase 2/Phase 3 | |
Recruiting |
NCT04054414 -
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT06000592 -
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
|
N/A | |
Completed |
NCT02325414 -
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
|
Phase 2 | |
Recruiting |
NCT02034669 -
Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment
|
Phase 1/Phase 2 | |
Terminated |
NCT02232165 -
Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury
|
N/A | |
Completed |
NCT02260713 -
Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.
|
Phase 1/Phase 2 | |
Completed |
NCT01502631 -
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
|
Phase 2 |